Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Bevacizumab in Recurrent or Metastatic Head and Neck Cancer
NCT00409565Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Sep 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00409565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409565.